Carbinoxamine extended-release - Tris Pharma

Drug Profile

Carbinoxamine extended-release - Tris Pharma

Alternative Names: Carbinoxamine maleate extended-release - Tris Pharma; Karbinal ER

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tris Pharma
  • Class Antiallergics; Antihistamines; Chlorobenzenes; Dimethylamines; Ethanolamines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 13 Aug 2015 Launched for Perennial allergic rhinitis (In children) in USA (PO)
  • 13 Aug 2015 Launched for Seasonal allergic rhinitis (In children) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top